cancer Incidence and Mortality in Ardabil: Report of an Ongoing Population-Based Cancer Registry in Iran, 2004-2006 by بابایی, مسعود et al.
Iranian J Publ Health, Vol. 38, No.4, 2009, pp.35-45 
35 
Cancer Incidence and Mortality in Ardabil: Report of an 
Ongoing Population-Based Cancer Registry in Iran, 2004-2006 
 
M Babaei 1,2, H Jaafarzadeh1, AR Sadjadi 2, F Samadi 2, A Yazdanbod 1, M Fallah 2, S Aghlmandi 1, 
R Ramezani 3, J Haukka 4, SH Hekmat 1, R Didevar 1, 2, B Shokoohi 1, *R Malekzadeh 2 
 
1Health Deputy, Ardabil University of Medical sciences, Ardabil, Iran 
2Digestive Disease Research Center (DDRC), Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 
3Ministry of Health and Medical Education, Iran, CDC, Cancer Office, Tehran, Iran 
4International Agency for Research on Cancer, Data Analysis and Interpretation Group (DEA), Lyon, France 
 
(Received 20 Jul 2009; accepted 22 Oct 2009) 
 
Abstract 
Background: Ardabil cancer registry is the first population-based cancer registry in Iran that was established in 2000. The 
first report from this registry revealed that Ardabil has one of the highest rate of gastric cardia cancer and the lowest rate of 
cervical cancer in the world. We aim to update the cancer incidence in this area by the second follow up report from this registry. 
Method: Data on all newly diagnosed cancer cases between 2004 and 2006 were actively collected. CanReg4 software was 
used for data entry and the data of cancer-related death were obtained from the comprehensive death registry system. 
Results: More than 4300 new cases were registered during 3 years. Diagnosis of cancer was based on histopathology in 69%, 
clinical investigation 8%, clinical only 5%, and Death Certificate Only (DCO) in 18% of cases. In terms of age-standardized 
rate (/100,000), the five leading cancers in men (excluding skin cancer) were stomach (51.8), esophagus (19.5), bladder 
(13.1), lung and bronchus (10.8), and colorectal (9.6); in women, they were stomach (24.9), esophagus (19.7), breast (11.9), 
colon and rectum (7.4), and brain tumors (6.9). According to death registration data, upper gastrointestinal cancers constituted 
more than 43% of cancer-related death in Ardabil. 
Conclusions: The ASR for gastric cancer is among the highest rate for this cancer in male and female in the world. Most of 
the cancers, especially in female, have a significant increase compared to previous report from Ardabil. This is most likely 
due to the change in the registration practice. 
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Introduction 
Cancer is one of the leading causes of death glob-
ally (1), according WHO about 7.5 million peo-
ple have died of cancer in 2007 and close to 85 
million will die of cancer in the next 10 yr and 
in year 2015, the yearly death number is expected 
to rise to 9 million and increase further to 11.5 
million in 2030 (2). According to national death 
registry report of Iran in 2004 cancer was the sec-
ond cause of non-accidental death in the country 
(3). It is estimated that each year more than 51000 
cases of cancer are diagnosed and 35,000 deaths 
due to cancer occur which is the second highest 
number of cancer death in Eastern Mediterranean 
Region of WHO (4). This relatively low current 
incidence rates is at least partly due to incomplete 
registration and diagnosis (5).We should expect 
an increase in the incidence of cancer in future 
because of increasing life expectancy and adoption 
of western type life style. The first important task 
for cancer control program is to establish popula-
tion based cancer registry, which systemically and 
continuously collect and store information about 
type, and location of new cancer cases occurring 
in defined population in a specific geographic area 
and could periodically analyze and report the 
results (6). In year 2000,  population based cancer 
registries were established in five provinces of 
Iran (5, 7, 8) and the first report of these cancer 
registries were published in subsequent years which 
permitted a better estimates of cancer incidence and 
mortality from Iran (4, 9-12). The result of these 
reports revealed that squamous cancer of esopha-
gus which was very common and among the highest 
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rate of cancer ever reported in the world 30 yr ago 
in Northeast Iranian Turkmen plain has declined 
sharply (11), while gastric cancer specially the car-
dia type was found to be very common in Ardabil 
with the rate highest among all other reported rates 
in the world. 
We aimed to present the second report from Arda-
bil cancer registry in order to update the inci-
dence and mortality and describe the trend (12). 
 
Materials and Methods 
Ardabil cancer registry (ACR) is a population-
based cancer registry that has been established 
in 2000 by Digestive Diseases Research Center 
(DDRC) of Tehran University of Medical Sciences 
(TUMS) with collaboration of Ardabil University 
of Medical Sciences (ARUMS) and Interna-
tional Agency for Research on Cancer (IARC). 
The population covered by the registry comprises 
9 urban districts and their surrounding rural areas, 
Ardabil province is located in north-west of Iran, 
an area 50 kilometers inland from the western 
Caspian Sea shoreline, according to the 2006 
census (Fig. 1), is 1,228,155, 1.9% of the total 
population of Iran. The population of Ardabil is 
relatively young, with 76% below the age of 40 yr 
almost all of the population is Shi’a Muslim and 
more than 98% of them have Azeri ethnicity, 
which is a branch of Aryan Caucasian ancestry. 
 
Fig. 1: Ardabil population, 2006 census 
 
Data on all newly diagnosed cancer cases (only 
permanent residents of Ardabil Province) in 2004 
to 2006 were actively collected. The ACR pro-
vides data on cancer incidence and stage at diag-
nosis from hospitals, pathology laboratories, radi-
ology centers, ambulatory surgical centers, chemo-
therapy facilities, Drugs and Alcohol Investigation 
Unit, and physicians’ offices. There are 14 hospitals 
with more than 1700 active beds in this province. 
ACR has appointed one trained personnel in each 
of 7 main hospitals of the province, to prepare 
cancer data and send them to ACR monthly. 
ARUMS has lunched the family physicians’ (FPs’) 
program in almost all the rural areas of Ardabil 
province since 2004 to provide more effective medi-
cal care for people and provide the necessary 
medical facilities for patients. All the rural popu-
lation has been covered by medical insurance and 
all referral should pass through FPs’. All FPs’ are 
suppose to report cancer data to ACR during the 
referral for cancer patients in FPs’ system. There 
are 4 categories of information collected by the re-
gistry: Patient demographics, tumor (cancer) iden-
tification, treatment and outcome of patient. 
The majority of cancer cases among Ardabil pro-
vince residents, which were diagnosed in other pro-
vinces, were added in the ACR database through 
sharing of cancer incidence data among provinces 
specially data from Tabriz and Tehran. Cases re-
ported to ACR initially were checked for duplica-
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tion reports and then were defined by the codes in-
cluded in the third edition of the International Clas-
sification of Diseases for Oncology (ICD-O III) 
before entering to database (13). Persian version of 
CanReg4 software was used for data entry and 
data was checked with IARC check program (14). 
Incidence rates were age-adjusted to the world’s 
2000 standard population in 18 age categories 
of 5 yr each (0-4, 5-9, .., 85+), and expressed per 
100,000. Incidence rate and age-standardized rate 
(ASR) has been calculated according to the years 
observed, gender, and topography site and adjusted 
for the cases of unknown age. Correction for un-
known age cases was carried out by multiplying the 
standardized rate, based on cases of known age, by 
T/K where T is the total number of cases of cancer 
of the same type in persons of the same sex and K is 
the number occurring in persons of known age (15). 
ASR has been calculated with direct method and in- 
direct method of standardization to compare with the 
previous studies and the national report of cancer 
occurrence in Iran. Cumulative risk calculated based 
on Day’s (1987) equation for age periods of 0-64 
and 0-74 yr for each gender and cancer sites (16). 
The leading causes of death from cancer and cancer 
mortality rates from 2004 to 2006 were obtained 
using data from the comprehensive death registry 
system of Ardabil province and had been compared 
with cancer registry data to reduce misclassification 
of causes of death. Death registration program of 
Ardabil Province is a part of the national program 
with more than 75% coverage in Iran (17, 18). 
Quality of Data 
More than 7200 reports of cancer occurrence were 
submitted in ACR from 2004 to 2006. After omit-
ting duplicate cases there were 4363 new cases 
registered in ACR during the study period, the no-
tification per case ratio was 1.7 and the number of 
new cases registered in the study period was, 1442, 
1484, and 1437 respectively for 2004, 2005, and 
2006. During 3 yr, the cases registered based on 
Microscopic Verification (MV) has improved from 
58.7% to 81.5% and cases registered based on 
Death Certificate Only (DCO) has been decreased 
from 22.5% to 9.2% subsequently. In total cases re-
gistered during 3 yr, base of the diagnosis was his-
topathological (MV) in 69%, DCO in 18%, Clinical 
investigation in 8% and Clinical only in 5% of cases. 
Some cancer types with more than 80% evidences 
of MV were the skin (97.1%), thyroid (92.1%), 
rectum (91.9%), lymph nodes (82.9%), and ovary 
(80.7%) (Table 1). The cancer sites that were re-
gistered lower than 50% based on MV were the 
bronchus and lung (32.7%), small intestine (35.5%), 
pancreas (32.7%) and liver (19.7%). In some 
cancer sites such as small intestine and liver, more 
than 50% of cases were registered based on DCO 
reports. Some cancer cases that were registered 
mainly based on clinical investigation were pan-
creas (49.1%) and brain (31.6%). 
Some indices about data quality in the 3 yr period 
are shown in Table 2. Percentage of unknown mor-
phology (code 8000.3-8000.9) decreased from 
38% to 17% respectively from 2004 to 2006. 
Table 1: Methods of diagnostic verification (%) by cancer site, 2004-2006 
Topography Microscopic Clin. Invest./Ult Sound Clinical only DCO Unknown 
Stomach 72.2 4.0 5.6 17.9 0.2 
Esophagus 76.9 4.3 4.8 13.8 0.2 
Skin 97.1 0.0 0.2 2.7 0.0 
Bladder 78.1 10.2 6.5 4.6 0.5 
Bronchus & lung 32.7 15.4 7.2 43.7 1.0 
Blood 54.1 0.9 5.8 37.2 1.9 
Breast 77.4 6.8 7.3 7.3 1.1 
Brain 53.8 31.6 4.7 9.4 0.6 
Colon 77.9 9.1 6.5 6.5 0.0 
Lymph nodes 82.9 7.6 3.8 4.8 0.9 
Prostate 67.4 3.4 8.9 17.9 2.2 
Liver 19.7 23.5 1.2 54.3 1.2 
Kidney 64.9 19.5 6.5 7.8 1.3 
Rectum 91.8 4.1 2.7 1.4 0.0 
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Thyroid 92.1 0.0 3.2 4.8 0.0 
Ovary 80.7 10.5 7.0 1.7 0.0 
Pancreas 32.7 49.1 7.3 10.9 0.0 
Small intestine 35.5 6.4 0.0 58.1 0.0 
DCO= Death Certificate only, Clin.Invest.= Clinical Investigation, Ult sound= Ultra sound 
 
Table 2: Data quality of cancer registry by year of 
registration 
 
2004 2005 2006 3 yr Data quality index 
% % % % 
Unknown sex 0.3 0.1 0.3 0.2 
Unknown age 2.7 2.5 2.7 1.3 
Unknown site of  
Origin (80.9) 7.1 8.7 3.2 6.4 
Unknown  
Morphology (8000.3-9) 38 33.9 17.2 29.8 
Microscopic Verification 58.7 63.1 81.5 67.2 
Death Certificate Only 22.5 22.2 9.2 18.0 
 
Results 
 
Cancer Incidence 
Of the total of 4363 cases that were registered, 
2588 (59.3%) cases were male and 1765 (40.5%) 
cases were female, with sex ratio of 1.47. The mean 
(±SD) age at the time of first diagnosis was 62.1 
(±16.9) yr for males and 59.8 (±18.4) for females 
[for both sex mean age was 59.8 (±17.8)]. Fig. 2 
shows the age-specific crude rate of all cancer sites 
by sex rising with age with a little notching in the 
age group 80-84 in women. 
In men, the leading primary cancer sites in terms 
of ASR (excluding skin cancer) were stomach, 
esophagus, bladder, lung, and colorectal (Table 3). 
In women, also stomach was the most common 
cancer site, followed by esophagus, breast, colo-
rectal, and central nervous system (CNS) (Table 4). 
Table 5 compares the incidence rates of invasive 
cancers in this study with the previous cancer sur-
vey in Ardabil between 1996 and 1999. This table 
reveals that approximately all the cancers has in-
crease in the recent cancer data. 
 
Cancer Mortality 
More than 13,630 deaths were registered during 
2004 to 2006 in comprehensive death registration 
of Ardabil province. Annual Cancer related deaths 
ranged between 14 to 16 percent of all deaths dur-
ing the study period in Ardabil. Death due to 
cancer was registered for 2111 cases (15.5%) in 
the study period. Garbage codes in death certificates 
consist of 20.5% of registered cases. The mean age 
(±SD) for cancer related death was 63.5 (±16.8) 
[male 64.4 (±16.4); female 61.6 (±17.5)]. 
The leading cancer sites in men in terms of crude 
mortality rate (MR) were stomach, esophagus, and 
lung (Table 6). In women, the leading killer cancer 
sites were similar to men. 
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Fig. 2: Age-specific incidence curve by sex, all sites, Ardabil, 2004-6 
Table 1: Countinued…
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Table 3: Age specific crud rate, Crud and Age adjusted incidence rates for Male in Ardabil Province_2004-6 
 
Primary Site 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
Total 
Count 
Freq 
% 
Crud 
Rate 
ASR 
/100,000 
Stomach 0.0 0.0 0.0 0.8 1.3 1.1 1.4 3.3 11.7 37.8 67.6 107.5 227.7 356.1 484.1 496.2 631.5 538.8 727 27.8 38.3 51.8 
Esophagus 0.0 0.0 0.0 0.4 0.4 1.1 0.7 1.6 7.4 13.5 21.9 38.9 99.8 133.5 148.7 206.4 160.4 251.4 269 10.3 14.2 19.5 
Other skin 0.7 0.6 0.4 0.4 0.4 1.6 2.7 6.5 3.2 8.1 25.6 38.9 69.1 77.9 128.3 99.2 180.4 610.6 230 8.8 12.1 17.9 
Bladder 0.0 0.6 0.0 0.0 0.9 0.5 0.7 6.5 5.3 13.5 18.3 48.0 43.5 61.2 90.4 107.2 140.3 251.4 179 6.8 9.4 13.1 
Lung, trachea 
& bronchus 
0.0 0.0 0.0 0.4 0.4 0.0 0.7 3.3 4.2 16.2 25.6 32.0 33.3 61.2 84.6 91.3 110.3 71.8 151 5.8 7.9 10.8 
Colorectal 0.0 0.0 0.0 1.5 0.0 3.7 4.7 4.1 11.7 10.8 9.1 20.6 38.4 38.9 72.9 95.3 70.2 107.8 144 5.5 7.6 9.6 
Brain, nervous 
system 
1.4 0.0 1.7 0.8 3.1 4.8 2.7 4.9 5.3 18.9 20.1 4.6 30.7 22.3 23.3 31.8 10.0 35.9 104 4.0 5.5 7.0 
Luekemia 1.4 3.1 2.2 2.7 1.3 1.6 4.7 4.1 1.1 4.0 14.6 16.0 17.9 11.1 29.2 35.7 30.1 71.8 91 3.5 4.8 5.8 
Prostate 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 4.0 1.8 2.3 20.5 41.7 61.2 115.1 80.2 71.8 89 3.4 4.7 5.7 
NHL 1.4 0.6 0.4 1.1 0.9 2.1 1.4 1.6 1.1 9.4 7.3 4.6 12.8 22.3 11.7 27.8 30.1 35.9 59 2.3 3.1 4.0 
Liver 0.0 0.0 0.0 0.8 0.4 0.0 0.0 0.0 1.1 4.0 11.0 9.1 20.5 25.0 11.7 23.8 30.1 35.9 48 1.8 2.5 3.7 
Kidney 2.1 0.0 0.4 0.4 0.0 0.5 0.0 0.8 4.2 2.7 9.1 4.6 5.1 22.3 8.7 23.8 30.1 35.9 43 1.6 2.3 3.1 
Larynx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 5.5 6.9 15.4 13.9 2.9 7.9 0.0 0.0 22 0.8 1.2 1.8 
Pancreas 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 2.7 5.5 4.6 10.2 5.6 8.7 27.8 10.0 0.0 25 1.0 1.3 1.8 
Bone 0.0 0.6 0.4 4.2 2.6 0.5 1.4 0.8 1.1 0.0 0.0 4.6 0.0 11.1 5.8 0.0 0.0 35.9 33 1.3 1.7 1.7 
Small 
intestine 
0.7 0.6 0.0 0.0 0.0 0.0 1.4 0.8 0.0 1.3 3.7 2.3 5.1 5.6 8.7 23.8 0.0 0.0 22 0.8 1.2 1.4 
Hodgkin 
Lymphoma 
0.0 0.6 0.9 0.8 0.0 0.0 0.7 0.0 1.1 4.0 1.8 2.3 5.1 0.0 5.8 4.0 10.0 0.0 18 0.7 0.9 1.1 
Testis 0.0 0.0 0.0 0.0 1.8 1.6 2.7 2.5 2.1 1.3 0.0 2.3 0.0 2.8 0.0 0.0 20.0 0.0 21 0.8 1.1 1.1 
Multiple 
Myeloma 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 7.7 5.6 8.7 7.9 10.0 0.0 13 0.5 0.7 0.9 
Melanoma of  
skin 
0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.8 1.1 1.3 5.5 2.3 0.0 5.6 0.0 4.0 20.0 0.0 13 0.5 0.7 0.9 
Nasopharynx 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 2.7 0.0 4.6 5.1 2.8 8.7 0.0 0.0 0.0 12 0.5 0.6 0.9 
Connective &  
soft tissue 
0.0 0.0 0.4 0.0 0.9 0.0 2.0 0.0 2.1 1.3 0.0 4.6 5.1 0.0 0.0 0.0 0.0 0.0 13 0.5 0.7 0.8 
Thyroid 0.0 0.0 0.4 0.0 0.4 0.5 0.7 0.0 0.0 0.0 3.7 0.0 0.0 0.0 11.7 4.0 0.0 0.0 11 0.4 0.6 0.6 
Lip 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.8 0.0 2.6 2.8 8.7 4.0 0.0 0.0 8 0.3 0.4 0.6 
Gallbladder 
etc. 
0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.0 1.3 1.8 0.0 0.0 8.3 0.0 4.0 0.0 0.0 8 0.3 0.4 0.6 
Kaposi 
sarcoma 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 4.6 2.6 0.0 2.9 4.0 0.0 0.0 6 0.2 0.3 0.5 
Pharynx 
unspecified 
0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 1.8 0.0 0.0 5.6 2.9 0.0 0.0 0.0 5 0.2 0.3 0.4 
Breast 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.8 2.3 0.0 0.0 0.0 0.0 10.0 0.0 4 0.2 0.2 0.3 
Tongue 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 2.8 0.0 7.9 10.0 0.0 5 0.2 0.3 0.3 
Other 
endocrine 
0.0 0.0 0.4 0.0 0.0 0.0 0.7 0.8 1.1 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 5 0.2 0.3 0.3 
Ureter 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 5.6 0.0 0.0 0.0 0.0 3 0.1 0.2 0.3 
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Other thoracic 
organs 
0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.8 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 3 0.1 0.2 0.2 
Other 
oropharynx 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 2.3 0.0 0.0 0.0 0.0 0.0 0.0 2 0.1 0.1 0.2 
Salivary 
glands 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.1 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 3 0.1 0.2 0.2 
Nose, sinuses 
etc. 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2 0.1 0.1 0.1 
Mesothelioma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 1 0.0 0.1 0.1 
Eye 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 10.0 0.0 2 0.1 0.1 0.1 
Other and 
unspecified 
2.1 1.2 0.9 2.3 0.4 0.0 0.0 0.0 0.0 0.0 14.6 6.9 12.8 52.9 40.8 23.8 100.2 0.0 80 3.1 4.2 5.4 
All sites 9.7 8.0 8.7 17.9 16.2 23.8 35.8 51.5 81.8 176.7 292.2 395.5 737.0 1046.1 1350.3 1572.1 1774.3 2262.9 2619 100.0 137.9 184.1 
All sites but 
Skin 
9.0 7.4 8.3 17.5 15.8 22.3 33.1 45.0 78.6 168.6 266.6 356.7 667.9 968.2 1222.0 1472.8 1593.8 1652.3 2400 91.6 126.3 167.1 
 
Table 4: Age specific crud rate, Crud and Age adjusted incidence rates for Female in Ardabil Province_2004-6 
 
Primary Site 
0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
Total 
Count 
Freq 
% 
Crud 
Rate 
ASR 
/100,000 
Stomach 0.0 0.0 0.0 0.4 0.0 1.7 5.0 4.4 5.4 13.0 45.6 63.9 121.7 124.4 225.7 215.9 216.6 326.3 311 17.3 17.0 24.9 
Esophagus 0.0 0.0 0.0 0.4 0.0 2.8 2.2 1.8 8.6 14.3 34.2 70.3 77.7 95.7 123.5 221.2 156.4 293.6 248 13.8 13.6 19.7 
Skin But 
Melanoma 0.0 0.0 0.0 0.4 0.4 0.6 1.4 3.5 7.5 13.0 14.7 29.8 54.4 54.2 116.4 121.1 108.3 228.4 165 9.2 9.0 13.1 
Breast 0.0 0.0 0.0 0.4 0.9 6.1 13.6 26.3 35.4 20.8 40.7 19.2 15.5 19.1 14.1 21.1 24.1 163.1 176 9.8 9.6 12.0 
colorectal 0.0 0.0 0.0 0.0 0.4 0.5 2.1 4.4 7.5 5.2 19.6 23.4 28.5 44.7 38.8 68.5 36.1 32.6 97 5.4 5.3 7.4 
Brain, nervous 
system 1.5 1.9 1.4 1.6 1.3 1.7 4.3 5.3 7.5 15.6 16.3 10.6 23.3 28.7 35.3 10.5 12.0 32.6 96 5.4 5.2 6.9 
Lung, trachea 
& bronchus 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.9 2.1 5.2 9.8 25.6 18.1 22.3 38.8 21.1 36.1 32.6 60 3.3 3.3 4.8 
Ovary 0.0 0.0 0.9 0.4 1.8 3.9 2.2 3.5 7.5 10.4 13.0 8.5 0.0 16.0 3.5 10.5 0.0 32.6 58 3.2 3.2 3.9 
Thyroid 0.0 0.0 0.9 0.8 1.8 0.6 7.9 7.9 3.2 1.3 9.8 0.0 2.6 12.8 3.5 10.5 36.1 65.3 54 3.0 2.9 3.3 
Luekemia 1.5 0.0 3.2 1.2 0.4 1.7 2.2 1.8 4.3 2.6 6.5 6.4 15.5 6.4 14.1 21.1 12.0 0.0 51 2.8 2.8 3.3 
Kidney 2.2 0.0 0.0 0.0 0.0 1.1 0.7 2.6 2.1 6.5 1.6 4.3 10.4 12.8 7.1 10.5 0.0 65.3 35 2.0 1.9 2.9 
Liver 0.0 0.0 0.5 0.0 0.4 0.0 0.0 0.9 2.1 0.0 3.3 4.3 5.2 9.6 31.7 36.9 12.0 65.3 34 1.9 1.9 2.6 
Bladder 0.0 0.0 0.0 0.8 0.9 0.6 0.7 2.6 1.1 1.3 3.3 8.5 2.6 6.4 10.6 68.5 48.1 0.0 40 2.2 2.2 2.5 
Pancreas 0.0 0.0 0.0 0.0 0.4 0.6 0.0 0.0 1.1 2.6 0.0 10.6 7.8 9.6 24.7 15.8 24.1 32.6 29 1.6 1.6 2.3 
NHL 0.7 0.6 0.0 0.4 0.0 2.2 0.7 2.6 2.1 3.9 1.6 2.1 7.8 6.4 0.0 10.5 0.0 32.6 26 1.4 1.4 1.9 
Gallbladder etc. 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 1.1 1.3 3.3 0.0 10.4 16.0 10.6 10.5 12.0 0.0 21 1.2 1.1 1.7 
Cervix uteri 0.0 0.0 0.0 0.0 0.4 0.0 0.7 2.6 3.2 2.6 0.0 2.1 7.8 0.0 0.0 5.3 0.0 65.3 17 0.9 0.9 1.4 
Corpus uteri 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 2.1 0.0 4.9 6.4 5.2 9.6 0.0 0.0 12.0 0.0 17 0.9 0.9 1.3 
Multiple 
Myeloma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 3.2 3.9 0.0 4.3 7.8 0.0 3.5 0.0 12.0 0.0 14 0.8 0.8 1.1 
Bone 0.7 1.3 2.8 1.2 0.9 0.0 0.7 0.9 0.0 0.0 0.0 2.1 2.6 3.2 0.0 5.3 0.0 0.0 20 1.1 1.1 1.1 
Uterus 
unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.9 1.1 5.2 0.0 2.1 2.6 3.2 7.1 0.0 0.0 0.0 12 0.7 0.7 0.9 
Table 3: Continu d…
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Hodgkin 
Lymphoma 0.0 0.0 1.4 2.4 0.9 
1.1 0.0 0.9 0.0 0.0 1.6 2.1 0.0 0.0 3.5 5.3 0.0 0.0 18 1.0 0.9 0.8 
Connective & 
soft tissue 0.7 0.0 0.5 0.0 0.0 0.0 0.0 0.9 1.1 0.0 0.0 0.0 0.0 3.2 7.1 0.0 0.0 65.3 9 0.5 0.5 0.8 
Small intestine 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.9 0.0 0.0 0.0 0.0 2.6 3.2 3.5 15.8 12.0 0.0 9 0.5 0.5 0.6 
Tongue 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 2.6 0.0 0.0 0.0 0.0 32.6 3 0.2 0.2 0.4 
Melanoma of 
skin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 2.1 0.0 0.0 0.0 2.6 0.0 0.0 5.3 0.0 0.0 5 0.3 0.3 0.3 
Nasopharynx 0.0 0.0 0.0 0.4 0.0 0.6 0.7 0.0 0.0 0.0 0.0 2.1 0.0 3.2 0.0 0.0 0.0 0.0 5 0.3 0.3 0.3 
Larynx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 12.0 0.0 4 0.2 0.2 0.3 
Tonsil 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.6 2.1 0.0 0.0 0.0 0.0 0.0 0.0 3 0.2 0.2 0.2 
Other thoracic 
organs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 2 0.1 0.1 0.2 
Lip 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 2.1 0.0 0.0 0.0 0.0 0.0 0.0 2 0.1 0.1 0.2 
Pharynx 
unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.5 0.0 0.0 3 0.2 0.2 0.2 
Kaposi 
sarcoma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 3.5 0.0 0.0 0.0 2 0.1 0.1 0.2 
Mouth 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 2 0.1 0.1 0.1 
Other 
oropharynx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 1 0.1 0.1 0.1 
Nose, sinuses etc 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 1 0.1 0.1 0.1 
Ureter 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1 0.1 0.1 0.1 
Other and 
unspecified 3.6 1.3 0.5 1.6 0.0 1.1 1.4 0.0 0.0 0.0 0.0 10.6 2.6 0.0 24.7 31.6 84.2 163.1 50 2.8 2.7 3.7 
All sites 10.9 5.2 12.1 12.7 12.4 28.7 50.2 85.9 121.1 135.3 251.0 347.1 468.6 561.6 793.6 1016.4 902.5 1761.8 1794 164.7 98.1 134.3 
All sites but 
Skin 10.9 5.2 12.1 12.3 11.9 28.1 48.8 82.4 113.6 122.3 236.3 317.3 414.3 507.3 677.2 895.3 794.2 1533.4 1635 150.1 89.4 121.7 
 
Table 5: Comparison of 10 leading cancers in Ardabil in two periods of time (1996-9 and 2004-6) 
 
Female Male 
Age-standardized rate Age-standardized rate Cancer 1996-9 2004-6 Cancer 1996-9 2004-6 
Stomach 25.4 24.7 Stomach 49.1 51.8 
Esophagus 14.4 19.9 Esophagus 15,4 20.0 
Breast 7.6 11.9 Bladder 7.6 13.1 
Colorectal 5.9 7.4 Lung 7.9 10.8 
CNS 3.1 6.8 Colorectal 7.9 9.6 
Lung 3.6 4.8 CNS 4.4 7.0 
Gallbladder 2.3 1.7 Leukemia -- 5.8 
Ovary 0.8 3.9 Prostate 3.4 5.7 
Leukemia -- 3.3 Non-Hodgkin Lymp.NOS 2.8 4 
Thyroid 1.0 3.3 Liver 1.8 3.7 
 
Table 4: C ntinued…
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Table 6: Mortality rates by cancer site and sex, Ardabil, 2004-6 
 
Female Male 
Total Freq Total Freq 
Cancer 
n % 
Crude 
Mortality 
Rate 
ASMR 95% CI Cancer 
n % 
Crude 
Mortality 
Rate 
ASMR 95% CI 
Stomach 206 28.5 11.3 16.3 13.9 18.6 Stomach 465 33.6 24.5 32.2 29.1 35.3 
Esophagus 102 14.1 5.6 7.7 6.1 9.2 Esophagus 179 12.9 9.4 12.9 10.9 14.9 
Lung 55 7.6 3.0 4.3 3.1 5.4 Lung 128 9.2 6.7 9.1 7.4 10.8 
Hematologic 
neoplasms 
57 7.9 3.1 3.9 2.8 4.9 
Hematologic 
neoplasms 
107 7.7 5.6 6.7 5.3 8.1 
Breast 36 4.9 1.9 2.6 1.7 3.5 Liver 46 3.3 2.4 3.3 2.3 4.4 
Liver 32 4.4 1.7 2.4 1.5 3.2 Colorectal 52 3.7 2.7 3.3 2.4 4.3 
Colorectal 21 2.9 1.1 1.6 0.9 2.3 CNS 47 3.4 2.5 3.1 2.1 3.9 
CNS 21 2.9 1.1 1.5 0.8 2.1 Prostate 45 3.2 2.4 2.9 1.9 3.8 
Small intestine 13 1.8 0.7 0.8 0.4 1.3 Bladder 22 1.6 1.2 1.4 0.8 2.8 
Pancreas 9 1.2 0.5 0.7 0.2 1.2 Pancreas 15 1.1 0.8 1.1 0.5 1.6 
Kidney 9 1.3 0.5 0.6 0.2 1.1 Bone 15 1.1 0.8 1.0 0.4 1.6 
Gallbladder etc. 7 1.0 0.4 0.6 0.2 1.1 Small intestine 16 1.2 0.8 1.0 0.5 1.5 
Corpus uteri 8 1.1 0.4 0.5 0.2 0.9 
Pharynx 
unspecified 
8 0.6 0.4 0.6 0.2 1.0 
Bladder 6 0.8 0.3 0.5 0.1 0.9 Mouth 5 0.4 0.3 0.3 0.0 0.5 
Ovary 6 0.8 0.3 0.4 0.1 0.8 Nasopharynx 3 0.2 0.2 0.3 0.0 0.6 
Thyroid 4 0.6 0.2 0.3 0.0 0.7 
Connective & soft 
tissue 
4 0.3 0.2 0.2 0.0 0.5 
Unknown 97 13.4 5.3 6.7 5.3 8.1 Unknown 163 11.8 8.6 11.0 9.2 12.8 
All sites 722 100.0 39.5 54.2 50.0 58.3 All sites 1385 100.0 72.9 94.5 89.2 99.9 
 
ASMR=Age-standardized mortality rate per 100,000. 
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Discussion 
Ardabil cancer registry is the first population based 
cancer registry in Iran and as expected the per-
centage of DCO cases has decline from  (22.5%) 
in the first year of activity to below 10% and  the  
MV% has increased from 58.7% in 2004 to more 
than 81% in 2006 (Table 2). Overall incidence of 
all cancers sites in terms of age-standardized rate 
in Ardabil was 184.1 in men and 134.3 in women 
(Tables 3 & 4); this is the highest allover cancer 
rate among all reported rates from other prov-
inces of Iran (12, 19, 20). 
The result of this study confirms our first report of 
cancer occurrence in Ardabil (9). Upper GI can-
cers alone account for 35.4% of all cancers in this 
region and Gastrointestinal tract cancers consti-
tutes 43% of all cancers in Ardabil. Stomach can-
cer which constitute close to one fourth (23.7%) 
of all malignancies in the province is the most com-
mon cancer. We have already shown that at least 
one third of all stomach cancer in Ardabil occurs 
in the cardia subsite with a surface area of only 5-
10% of the entire stomach. Therefore, the cancer 
incidence expressed as per unit of epithelial sur-
face area is extremely high. As a matter of fact the 
incidence of cardia cancer in Ardabil province of 
Iran is the highest recorded anywhere in the world 
and it provides an excellent opportunity to study 
the etiology of this cancer which has a rising inci-
dence throughout the world (10, 21). In Ardabil 
more than 80% of population has H pylori (HP) 
infection and Gastroesophageal reflux disease 
(GERD) (22). We have recently shown that both 
GERD and HP related atrophic gastritis contrib-
ute to etiology of gastric cardia cancer in Ardabil 
(23, 24). Therefore, any gastric cancer control 
program in Ardabil should be planned with the 
understanding that contrary to other high incidence 
area of gastric cancer like Japan and Korea with 
the non-cardia cancer as the most common type of 
stomach cancer; gastric cardia is the predominant 
type of gastric cancer in Ardabil Iran. 
Comparing the GI cancer rate from our first re-
port to the present study there is a significant in-
crease in GI tract cancers rates in Ardabil prov-
ince (Table 5), this is probably due to improve-
ment in the death and cancer registration prac-
tices and increasing availability of gastroenterolo-
gist and diagnostic endoscopy in the province; but 
it may at least partly be a real increase due to 
changes in dietary habits and lifestyle. There is 
now some evidence that the incidence of esophag-
eal adenocarcinoma (25), gastric cardia adenocar-
cinoma (9, 19), adenocarcinoma of colon (26) 
are increasing in Iran. 
The incidence of several other cancers (Table 5) 
is also on the rise; the most important one are 
Breast and ovarian cancers in female and male lung 
and prostate cancers have increased. In addition 
to better diagnosis and registration of these types 
of cancer in Ardabil during last 10 years an in-
creasing trend for breast and prostate cancer also 
has been reported from Iran (5). 
Another very interesting finding of our first cancer 
registry (9) report from Ardabil was the surpris-
ingly very low incidence of cervical cancer in fe-
male, a rate lower than any reported in the world. 
In this second report, although the incidence of 
this cancer has increased to more than tippled 
(ASR from 0.4 to 1.4), but it is still not among 
the first 15 cancers in female. The reason for this 
finding was thought to be due to the facts that 
Ardabil is one of the most religious cities in Iran, 
with >99% of residents being Shi’a Muslims with 
very strong dependence on family-based traditions 
and almost no extramarital sexual relations. 
Cancer mortality in Ardabil is much higher than 
mortality in developed countries. For example dur-
ing 2004 the one-year age-adjusted relative sur-
vival of patients with esophageal cancer were 32% 
for men and 34% for women in British Columbia 
(BC) in Canada, and 18% for men and 16% for 
women in Ardabil and the one-year age-adjusted 
relative survival rates for patients with gastric can-
cer was 48% for men and 46% for women in BC, 
and 15% for men and 21% for women in Arda-
bil (27). The higher mortality in Ardabil seems to 
be due to differences in cancer control systems in the 
two regions for example in Ardabil majority of can-
cers are in advance stages at the time of diagnosis.  
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Another reason for this difference in mortality may 
be due to differences in disease etiology, patient 
factors. The outcomes of upper GI cancers are 
poor for especially in Ardabil populations, and 
improvements in diagnosis and management are 
urgently needed. 
A screening program should be considered to re-
duce the burden of cancer in Ardabil. For upper GI 
endoscopy, though difficult and expensive to im-
plement, may be the best current possible method. 
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